Подагра. Диссертация Мишко МЮ. 2 оглавление введение глава обзор литературы значение внешнесредовых и генетических факторов в развитии гиперурикемии и подагры
 Скачать 5.03 Mb.
|
|
153 al.]. – DOI 10.1093/rheumatology/keq425 // Rheumatology. – 2011. – Vol. 50 (5). – P. 871 –878. 57. Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order Amish / P.F. McArdle, A. Parsa, Y.P. Chang. [et al.]. – DOI 10.1002/art.23752 // Arthritis Rheum. – 2008. – Vol. 58 (9). – P. 2874–2881. 58. Association of incident gout and mortality in dialysis patients / S.D. Cohen, P.L. Kimmel, R. Neff [et al.]. – DOI 10.1681/ASN.2007111256 // J Am Soc Nephrol. – 2008. – Vol. 19. – P. 2204–2210. 59. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study / A. Dehghan, A. Köttgen, Q. Yang [et al.]. – DOI 10.1016/S0140-6736(08)61343-4 // Lancet. – 2008. – Vol. 372 (9654). – P. 1953–1961. 60. Associations between Specific Redox Biomarkers and Age in a Large European Cohort: The MARK-AGE Project / D. Weber, W. Stuetz, O. Toussaint [et al.]. – DOI 10.1155/2017/1401452 // Oxid Med Cell Longev. – 2017. – Vol. 2017. – P. 1401452. 61. Bokhari В. Stress Marks on the Genome: Use or Lose? / B. Bokhari, S. Sharma. – DOI 10.3390/ijms20020364 // Int J Mol Sci. – 2019. – Vol. 20 (2). – P. 364. 62. Cells have distinct mechanisms to maintain protection against different reactive oxygen species: oxidative-stressresponse-genes / G.W. Thorpe, C.S. Fong, N. Alic [et al.]. – DOI 10.1073/pnas.0305888101 // PNAS. – 2004. – Vol. 101 (17). – P. 6564– 6569. 63. Characteristics, Comorbidities, and Potential Consequences of Uncontrolled Gout: An Insurance-Claims Database Study / M. Francis-Sedlak, B. LaMoreaux, L. Padnick- Silver [et al.]. – DOI 10.1007/s40744-020-00260-1 // Rheumatol Ther. – 2021. – Vol. 8 (1). – P. 183–197. 64. Chatterjee N. Mechanisms of DNA damage, repair, and mutagenesis / N. Chatterjee, G.C. Walker. – DOI 10.1002/em.22087 // Environ Mol Mutagen. – 2017. – Vol. 58 (5). – P. 235–263. 65. Common defects of ABCG2, a high-capacity urate exporter, cause gout: A function-based genetic analysis in a Japanese population / H. Matsuo, T. Takada, K. 154 Ichida [et al.]. – DOI 10.1126/scitranslmed.3000237 // Sci Transl Med. – 2009. – Vol. 1 (5). – P. 5ra11. 66. Contribution of caffeine to the homocysteine-raising effect of coffee: a randomized controlled trial in humans / P. Verhoef, W.J. Pasman, T. Van Vliet [et al.]. – DOI 10.1093/ajcn/76.6.1244 // Am J Clin Nutr. – 2002. – Vol. 76 (6). – P. 1244–1248. 67. Correlation of GLUT9 Polymorphisms With Gout Risk / Q. Meng, J. Yue, M. Shang [et al.]. – DOI 10.1097/MD.0000000000001742 // Medicine (Baltimore). – 2015. – Vol. 94 (44). – P. e1742. 68. Crystal structure of the crenarchaeal ExoIII AP endonuclease SisExoIII reveals a conserved disulfide bond endowing the protein with thermostability / Z. Yan, Z. Yuan, J. Ni [et al.]. – DOI 10.1016/j.bbrc.2017.06.116 // Biochem Biophys Res Commun. – 2017. – Vol. 490 (3). – P. 774–779. 69. Dalbeth N. The genetics of gout: towards personalised medicine? / N. Dalbeth, L.K. Stamp, T.R. Merriman. – DOI 10.1186/s12916-017-0878-5 // BMC Med. – 2017. – Vol. 15 (1). – P. 108. 70. Drug-induced hyperuricaemia and gout / C.B. Salem, R. Slim, N. Fathallah, H. Hmouda. – DOI 10.1093/rheumatology/kew293 // Rheumatology (Oxford). – 2017. – Vol. 56 (5). – P. 679–688. 71. Effect of genetic polymorphisms on development of gout / W. Urano, A. Taniguchi, E. Inoue [et al.]. – DOI 10.3899/jrheum.121244 // J Rheumatol. – 2013. – Vol. 40 (8). – P. 1374–1378. 72. Elliot A.J. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994 –2007 / A.J. Elliot, K.W. Cross, D.M. Fleming. – DOI 10.1136/ard.2008.096693 // Ann Rheum Dis. – 2009. – Vol. 68 (11). – P. 1728–1733. 73. Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort / V. Bhole, M. de Vera, M.M. Rahman [et al.]. – DOI 10.1002/art.27338 // Arthritis Rheum. – 2010. – Vol. 62 (4). – P. 1069–1076. 74. Epydemiology of Gout: is the Incidence Rising? / E. Arromdee, C.J. Michet, C.S. Crowson [et al.] // J Rheumatol. – 2002. – Vol. 29 (11). – P. 2403–2406. 155 75. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology 2013 / G. Montalescot, U. Sechtem, S. Achenbach. – DOI 10.1093/eurheartj/eht296 // Eur Heart J. – 2013. – Vol. 34 (38). – P. 2949–3003. 76. Ethnic differences in ATPbinding cassette transporter, sub-family G, member 2 (ABCG2/BCRP): genotype combinations and estimated functions / M. Sakiyama, H. Matsuo, Y. Takada [et al.]. – DOI 10.2133/dmpk.DMPK-14-SC-041 // Drug Metab Pharmacokinetics. – 2014. – Vol. 29. – P. 490–492. 77. Folate Deficiency and Gene Polymorphisms of MTHFR, MTR and MTRR Elevate the Hyperhomocysteinemia Risk / W.X. Li, F. Cheng, A.J. Zhang [et al.]. – DOI 10.7754/Clin.Lab.2016.160917 // Clin Lab. – 2017. – Vol. 63 (3). – P. 523–533. 78. Functional polymorphisms of the ABCG2 Gene Are Associated with Gout Disease in the Chinese Han Male Population / D. Zhou, Y. Liu, X. Zhang [et al.]. – DOI 10.3390/ijms15059149 // International Journal of Molecular Sciences. – 2014. – Vol. 15 (5). – P. 9149–9159. 79. Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk / H. Ito, K. Matsuo, N. Hamajima [et al.]. – DOI 10.1093/carcin/bgh153 // Carcinogenesis. – 2004. – Vol. 25 (8). – P. 1395–1401. 80. Generalized Multifactor Dimensionality Reduction (gmdr_beta_0.6.2) // Sourceforge : [site]. – URL: https://sourceforge.net/projects/gmdr/ (дата обращения 19.03.2017). 81. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations / A. Köttgen, E. Albrecht, A. [et al.]. – DOI 10.1038/ng.2500 // Nat Genet. – 2013. – Vol. 45 (2). – P. 145–154. 82. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response / C.C. Wen, S.W. Yee, X. Liang [et al.]. – DOI 10.1002/cpt.89 // Clin Pharmacol Therapy. – 2015. – Vol. 97 (5). – P. 518–525. 83. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes / H. Matsuo, K. Yamamoto, H. Nakaoka 156 [et al.]. – DOI 10.1136/annrheumdis-2014-206191 // Ann Rheum Dis. – 2015. – Vol. 74 (2). – P. 1–8. 84. Genotype-based changes in serum uric acid affect blood pressure / A. Parsa, E. Brown, R.W. Matthew [et al.]. – DOI 10.1038/ki.2011.414 // Kidney Int. – 2012. – Vol. 81 (5). – P. 502–507. 85. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile / H.K. Choi, M.A. de Vera, E. Krishnan. – DOI 10.1093/rheumatology/ken305 // Rheumatology (Oxford). – 2008. – Vol. 47 (10). – P. 1567–1570. 86. Gout classification criteria: an American College of Rheumatology / European League Against Rheumatism collaborative initiative 2015 / T. Neogi, T. Jansen, N. Dalbeth [et al.]. – DOI 10.1136/annrheumdis-2015-208237 // Ann Rheum Dis. – 2015. – Vol. 74 (10). – P. 1789–1798. 87. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999 / T.R. Mikuls, J.T. Farrar, W.B. Bilker [et al.]. – DOI 10.1136/ard.2004.024091 // Ann Rheum Dis. – 2005. – Vol. 64 (2). – P. 267–272. 88. Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide- binding domain and can be corrected with small molecules / O.M. Woodward, D.N. Tukaye, J. Cui [et al.]. – DOI 10.1073/pnas.1214530110 // Proc Nat Acad Sci USA. – 2013. – Vol. 110 (13). – P. 5223–5228. 89. Gupta M.K. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy. Review / M.K. Gupta, J.A. Singh. – DOI 10.1007/s40265-019-01081-5 // Drugs. – 2019. – Vol. 79 (5). – P. 531–541. 90. Haplotype-Based Case–Control Study on Human Apurinic/Apyrimidinic Endonuclease 1/Redox Effector Factor-1 Gene and Essential Hypertension / T. Naganuma, T. Nakayama, N. Sato [et al.]. – DOI 10.1038/ajh.2009.221 // American Journal of Hypertension. – 2010. – Vol. 23 (2). – P. 186–191. 91. High Uric Acid Activates the ROS-AMPK Pathway, Impairs CD68 Expression and Inhibits OxLDL-Induced Foam-Cell Formation in a Human Monocytic Cell Line, THP-1 / C. Luo, X. Lian, L. Hong [et al.]. – DOI 10.1159/000452567 // Cell Physiol Biochem. – 2016. – Vol. 40 (3-4). – P. 538–548. 157 92. Hiraoka M. Genetic polymorphisms and folate status / M. Hiraoka, Y. Kagawa. – DOI 10.1111/cga.12232 // Congenit Anom (Kyoto). – 2017. – Vol. 57 (5). – P. 142– 149. 93. Homocysteine and Stroke Risk: Modifying Effect of Methylenetetrahydrofolate Reductase C677T Polymorphism and Folic Acid Intervention / M. Zhao, X. Wang, M. He [et al.]. – DOI 10.1161/STROKEAHA.116.015324 // Stroke. – 2017. – Vol. 48 (5). – P. 1183–1190. 94. Homocysteine is a marker for metabolic syndrome and atherosclerosis / B. Sreckovic, V.D. Sreckovic, I. Soldatovic. [et al.]. – DOI 10.1016/j.dsx.2016.08.026 // Diabetes Metab Syndr. – 2017. – Vol. 11 (3). – P. 179–182. 95. Human renal organic anion transporter 4 operates as an asymmetric urate transporter / Y. Hagos, D. Stein, B. Ugele [et al.]. – DOI 10.1681/ASN.2006040415 // J Am Soc Nephrol. – 2007. – Vol. 18. – P. 430–439. 96. Hypertension and the risk of incident gout in a populationbased study: the atherosclerosis risk in communities cohor / M.A. McAdams-DeMarco, J.W. Maynard, A.N. Baer, J. Coresh. – DOI 10.1111/j.1751-7176.2012.00674.x // J Clin Hypertens (Greenwich). – 2012. – Vol. 14 (10). – P. 675–679. 97. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease / C. Borghi, E. Agabiti-Rosei, R.J. Johnson [et al.]. – DOI 10.1016/j.ejim.2020.07.006 // Eur J Intern Med. – 2020. – Vol. 80. – P. 1–11. 98. Hyperuricemia and Cardiovascular Disease / S. Zhang, Y. Wang, J. Cheng [et al.]. – DOI 10.2174/1381612825666190408122557 // Curr Pharm Des. – 2019. – Vol. 25 (6). – P. 700–709. 99. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation / R.J. Johnson, G.L. Bakris, C. Borghi [et al.]. – DOI 10.1053/j.ajkd.2017.12.009 // Am J Kidney Dis. – 2018. – Vol. 71 (6). – P. 851–865. 100. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking / R. Augustin, M.O. Carayannopoulos, 158 L.O. Dowd [et al.]. – DOI 10.1074/jbc.M312226200 // J Biol Chem. – 2004. – Vol. 279 (16). – P. 16229–16236. 101. Impact of the Ser326Cys polymorphism of the OGG1 gene on the level of oxidative DNA damage in patients with colorectal cancer / J. Kabzinski, A. Walczak, A. Dziki [et al.]. – DOI 10.5604/01.3001.0011.7486 // Pol Przegl Chir. – 2018. – Vol. 90 (2). – P. 13–15. 102. Izmirli M. A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk / M. Izmirli. – DOI 10.1007/s11033-012-2101-2 // Mol Biol Rep. – 2013. – Vol. 40 (1). – P. 625–637. 103. Keenan R.T. The biology of urate / R.T. Keenan. – DOI 10.1016/j.semarthrit.2020.04.007 // Semin Arthritis Rheum. – 2020. – Vol. 50 (3S). – P. S2 –S10. 104. Kramer H.M. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988 –1994 / H.M. Kramer, G. Curhan. – DOI 10.1053/ajkd.2002.33911 // Am J Kidney Dis. – 2002. – Vol. 40 (1). – P. 37–42. 105. Lesch-Nyhan Syndrome: Models, Theories, and Therapies / S. Bell, I. Kolobova, L. Crapper, C. Ernst. – DOI 10.1159/000449296 // Mol Syndromol. – 2016. – Vol. 7 (6). – P. 302–311. 106. Lesch-Nyhan syndrome: The saga of metabolic abnormalities and self-injurious behavior / N. Tewari, V.P. Mathur, D. Sardana, K. Bansal. – DOI 10.5582/irdr.2016.01076 // Intractable Rare Dis Res. – 2017. – Vol. 6 (1). – P. 65–68. 107. Li R. Dietary factors and risk of gout and hyperuricemia: a meta-analysis and systematic review. Meta-Analysis / R. Li, K. Yu, C. Li. – DOI 10.6133/apjcn.201811_27(6).0022 // Asia Pac J Clin Nutr. – 2018. – Vol. 27 (6). – P. 1344 –1356. 108. Liew S.C. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases / S.C. Liew, E.D. Gupta. – DOI 10.1016/j.ejmg.2014.10.004 // Eur J Med Genet. – 2015. – Vol. 58 (1). – P. 1–10. 159 109. Martín N.E. Hypouricemia and tubular transport of uric acid / N.E. Martín, V.G. Nieto. – DOI 10.3265/Nefrologia.pre2010.Oct.10588 // Nefrologia. – 2011. – Vol. 31 (1). – P. 44-50. 110. Merriman T.R. An update on the genetic architecture of hyperuricemia and gout. – DOI 10.1186/s13075-015-0609-2 // Arthritis Res Ther. – 2015. – Vol. 17 (1). – P. 98. 111. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations / M. Kolz , T. Johnson, S. Sanna [et al.]. – DOI 10.1371/journal.pgen.1000504 // PLoS Genet. – 2009. – Vol. 5 (6). – P. e1000504. 112. Metabolic syndrome and ischemic heart disease in gout / J. Vazguez-Mellado, C.G. Garsia, S.G. Vazguez [et al.]. – DOI 10.1097/01.rhu.0000129082.42094.fc // J Clin Rheumatol. – 2004. – Vol. 10 (3). – P. 105–109. 113. Metabolic syndrome, alcohol consumption and genetic factors are associated with serum uric acid concentration / B. Stiburkova, M. Pavlikova, J. Sokolova, V. Kozich. – DOI 10.1371/journal.pone.0097646 // PLoS. – 2014. – Vol. 9 (5). – P. e97646. 114. Methylenetetrahydrofolate reductase (MTHFR) c677t gene variant modulates the homocysteine folate correlation in a mild folate-deficient population / A.C. Pereira, I.T. Schettert, A.A. Morandini Filho [et al.]. – DOI 10.1016/j.cccn.2003.09.016 // Clin Chim Acta. – 2004. – Vol. 340 (1-2). – P. 99–105. 115. Mizuarai S. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2 / S. Mizuarai, N. Aozasa, H. Kotani. – DOI 10.1002/ijc.11669 // Int J Cancer. – 2004. – Vol. 109 (2). – P. 238–246. 116. Molecular Physiology of Urate Transport / M.A. Hediger, R.J. Johnson, H.H. Miyazaki, H. Endou. – DOI 10.1152/physiol.00039.2004 // Physiology. – 2005. – Vol. 20. – Р. 125–133. 117. MTHFR C677T and A1298C polymorphisms may contribute to the risk of Parkinson's disease: A meta-analysis of 19 studies / L. Liu, L. Zhang, L. Guo [et al.]. – DOI 10.1016/j.neulet.2017.10.060 // Neurosci Lett. – 2018. – Vol. 662. – P. 339–345. 160 118. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study / I.S. Mackenzie, I. Ford, A. Walker [et al.]. – DOI 10.1136/bmjopen-2016-013774 // BMJ Open. – 2016. – Vol. 6 (9). – P. e013774. 119. Multifactor Dimensionality Reduction (mdr-2.0_beta_8.3) // Sourceforge : site. – URL: https://sourceforge.net/projects/mdr/ (дата обращения 19.03.2017). 120. Multiple common and rare variants of ABCG2 cause gout / T. Higashino, T. Takada, H. Nakaoka [et al.]. – DOI 10.1136/rmdopen-2017-000464 // RMD Open. – 2017. – Vol. 3 (2). – P. e000464. 121. Nakagawa T. The effects of fruit consumption in patients with hyperuricaemia or gout. Review / T. Nakagawa, M.A. Lanaspa, R.J. Johnson. – DOI 10.1093/rheumatology/kez128 // Rheumatology (Oxford). – 2019. – Vol. 58 (7). – P. 1133 –1141. 122. Nazki F.H. Folate: metabolism, genes, polymorphisms and the associated diseases / F.H. Nazki, A.S. Sameer, B.A. Ganaie. – DOI 10.1016/j.gene.2013.09.063 // Gene. – 2014. – Vol. 533 (1). – P. 11–20. 123. Ndrepepa G. Uric acid and cardiovascular disease / G. Ndrepepa. – DOI 10.1016/j.cca.2018.05.046 // Clin Chim Acta. – 2018. – Vol. 484. – P. 150–163. 124. Nguyen K.V. Mutation in the Human HPRT1 Gene and the Lesch-Nyhan Syndrome / K.V. Nguyen, W.L. Nyhan. – DOI 10.1080/15257770.2015.1098660 // Nucleosides Nucleotides Nucleic Acids. – 2016. – Vol. 35 (8). – P. 426–433. 125. Nguyen K.V. Novel mutation in the human HPRT1 gene and the Lesch-Nyhan disease / K.V. Nguyen, R.K. Naviaux, W.L. Nyhan. – DOI 10.1080/15257770.2017.1395037 // Nucleosides Nucleotides Nucleic Acids. – 2017. – Vol. 36 (11). – P. 704–711. 126. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study / H.K. Choi, K. Atkinson, E.W. Karlson, G. Curhan. – DOI 10.1001/archinte.165.7.742 // Arch Intern Med. – 2005. – Vol. 165. – P. 742 –748. 161 127. Park J.A. ATIC Gene Polymorphism and Histologic Response to Chemotherapy in Pediatric Osteosarcoma / J.A. Park, H.Y. Shin. – DOI 10.1097/MPH.0000000000000802 // J Pediatr Hematol Oncol. – 2017. – Vol. 39 (5). – P. e270 –e274. 128. Plasma urate level is directly regulated by a voltagedriven urate efflux transporter URATv1 (SLC2A9) in humans / N. Anzai, K. Ichida, P. Jutabha [et al.]. |